Logo

STADA and Alvotech’s Uzpruvo (Biosimilar, Stelara) Obtains EC’s Approval for Immune-Mediated Diseases

Share this
STADA

STADA and Alvotech’s Uzpruvo (Biosimilar, Stelara) Obtains EC’s Approval for Immune-Mediated Diseases

Shots:

  • Followed by the CHMP’s positive opinion in Nov 2023 for Crohn’s disease, psoriasis and psoriatic arthritis, the EC has approved Uzpruvo across the EU and Iceland, Liechtenstein, and Norway 
  • The approval was based on the analytical & clinical results, data from the study (AVT04-GL-301) comparing the safety and efficacy of AVT04 vs Stelara for treating chronic plaque-type psoriasis demonstrating its similarity as well as results from the (AVT04-GL-101) study showing similar PK characteristics 
  • Additionally, Alvotech holds rights to develop and manufacture Uzpruvo while STADA is responsible for the commercialization in the EU as per the agreement signed in 2019 

Ref: Alvotech | Image: STADA

Related News:- Alvotech and Teva Reports the US FDA’s Acceptance of BLA for Review of AVT04, a Proposed Biosimilar to Stelara (ustekinumab)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions